Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2010, for Zeta Acquisition Corp. III (not Kura Oncology, Inc., as indicated in the metadata). The registrant is a Delaware corporation organized as a "blank check" company and a shell company in the development stage. Its sole business objective is to investigate and acquire a target company to achieve long-term growth potential. The company has no specific business plan other than to merge with an unidentified company and has generated no revenues since its inception on November 16, 2007.
Key Financial Metrics
| Metric | Value (Sep 30, 2010) | Value (Dec 31, 2009) |
|---|---|---|
| Cash and Cash Equivalents | $2,254 | $11,142 |
| Total Assets | $6,004 | $13,017 |
| Total Liabilities | $39,249 | $31,613 |
| Stockholders' Deficit | ($33,245) | ($18,596) |
| Notes Payable (Stockholders) | $35,000 | $25,000 |
| Net Loss (9 Months Ended Sep 30, 2010) | ($14,649) | ($12,529) |
| Cumulative Net Loss (Inception to Sep 30, 2010) | ($83,245) | N/A |
Liquidity: The company has minimal cash on hand ($2,254) and relies entirely on related party financing to fund operations. There are no revenues to support ongoing activities.
Material Changes vs. Prior Period
- Cash Position: Cash and cash equivalents decreased by approximately 80% from $11,142 at year-end 2009 to $2,254 at September 30, 2010.
- Liabilities: Total liabilities increased by $7,636, driven primarily by an additional $10,000 in notes payable issued to stockholders during the period.
- Operating Loss: The net loss for the nine months ended September 30, 2010, was $14,649, compared to $12,529 for the same period in 2009. This increase is attributed to interest expense and professional fees (legal, accounting, audit) required for SEC reporting.
- Accumulated Deficit: The accumulated deficit grew from ($68,596) to ($83,245) over the nine-month period.
Outlook, Risks, and Management Commentary
Going Concern: Management explicitly states that the company's ability to continue as a going concern is dependent on its ability to secure additional financing and/or complete a business combination. The financial statements do not include adjustments that might be necessary if the company cannot continue operations.
Capital Resources: The company anticipates incurring costs for filing Exchange Act reports and investigating acquisition targets. It plans to meet these costs through existing treasury funds, deferral of fees, or additional loans from stockholders and management. There is no assurance that additional funding will be available.
Risks:
- Blank Check Status: As a shell company with no operations, the company is subject to risks associated with "blank check" companies, including limitations on securities sales in certain jurisdictions.
- Target Selection: The company may acquire a financially unstable or early-stage company, exposing investors to high risk.
- Lack of Diversification: Management anticipates effecting only one business combination, meaning the company cannot offset losses from one venture with gains from another.
Unusual Items: The company utilizes office space and equipment of an officer/director at no cost, which management estimates to be de minimis.
Investor Verification Checklist
- Identity Discrepancy: Verify that the filing is for Zeta Acquisition Corp. III, not Kura Oncology, Inc., as the metadata suggested.
- Cash Runway: Confirm the sufficiency of the $2,254 cash balance to cover upcoming SEC filing fees and professional service costs.
- Related Party Debt: Review the terms of the $35,000 in notes payable to stockholders, which bear 6% interest and are due on demand.
- Going Concern Status: Assess the likelihood of securing the additional financing required to avoid insolvency before a business combination is completed.
- Target Search Progress: Determine if any specific acquisition targets have been identified or if discussions are still in preliminary stages.